RNAENFDRF TFA

Cat. No.: HY-P3429A

Molecular Formula: $C_{52}H_{74}F_3N_{17}O_{18}$

Molecular Weight: 1282.24

Sequence: Arg-Asn-Ala-Glu-Asn-Phe-Asp-Arg-Phe

Sequence Shortening: RNAENFDRF

Target: PKC

Pathway: Epigenetics; TGF-beta/Smad

Storage: Sealed storage, away from moisture

Powder -80°C 2 years

-20°C 1 year

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

RNAENFDRF (TFA)

SOLVENT & SOLUBILITY

In Vitro

H_2O : 50 mg/mL (38.99 mM; Need ultrasonic)

Preparing Stock Solutions	Mass / Solvent / Concentration	1 mg	5 mg	10 mg
	1 mM	0.7799 mL	3.8994 mL	7.7989 mL
	5 mM	0.1560 mL	0.7799 mL	1.5598 mL
	10 mM	0.0780 mL	0.3899 mL	0.7799 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

RNAENFDRF (βIIPKC624-632) TFA is conjugated to the cell permeable peptide TAT47-57, which can be used to form an inhibitory peptide SAMβA. SAMβA, a rationally designed selective antagonist of Mfn1-βIIPKC association. SAMβA is a selective inhibitor of mitofusin 1-βIIPKC association improves heart failure outcome in rats[1].

REFERENCES

[1]. Julio C B Ferreira A selective inhibitor of mitofusin 1-βIIPKC association improves heart failure outcome in rats. Nat Commun. 2019 Jan 18;10(1):329.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA